Protein Information

General Information of the Protein

Protein ID	PT01004
Protein Name	Alpha-1D adrenergic receptor
Secondarily Protein Name	Alpha-1A adrenergic receptor Alpha-1D adrenoreceptor Alpha-adrenergic receptor 1a
Gene Name	ADRA1D
Secondarily Gene Name	ADRA1A
Sequence	MTFRDLLSVSFEGPRPDSSAGGSSAGGGGGSAGGAAPSEGPAVGGVPGGAGGGGGVVGAGSGEDNRSSAGEPGSAGAGGDVNGTAAVGGLVVSAQGVGVGVFLAAFILMAVAGNLLVILSVACNRHLQTVTNYFIVNLAVADLLLSATVLPFSATMEVLGFWAFGRAFCDVWAAVDVLCCTASILSLCTISVDRYVGVRHSLKYPAIMTERKAAAILALLWVVALVVSVGPLLGWKEPVPPDERFCGITEEAGYAVFSSVCSFYLPMAVIVVMYCRVYVVARSTTRSLEAGVKRERGKASEVVLRIHCRGAATGADGAHGMRSAKGHTFRSSLSVRLLKFSREKKAAKTLAIVVGVFVLCWFPFFFVLPLGSLFPQLKPSEGVFKVIFWLGYFNSCVNPLIYPCSSREFKRAFLRLLRCQCRRRRRRRPLWRVYGHHWRASTSGLRQDCAPSSGDAPPGAPLALTALPDPDPEPPGTPEMQAPVASRRKPPSAFREWRLLGPFRRPTTQLRAKVSSLSHKIRAGGAQRAEAACAQRSEVEAVSLGVPHEVAEGATCQAYELADYSNLRETDI Show/Hide
Organism	Homo sapiens, Human
Protein Classification	Membrane receptor > Family A G protein-coupled receptor > Small molecule receptor (family A GPCR) > Monoamine receptor > Adrenergic receptor
Function	This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium. Show/Hide
Uniprot ID	Primary ID: P25100 Secondarily ID: Q9NPY0 Show/Hide
Ensembl ID	ENSG00000171873
HGNC ID	HGNC:280
Subcellular Location	Cell membrane

Map of Molecular Bioactivity Related to the Protein

Map of Molecular Bioactivity Related to the Protein Protein Cell Line Compound Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity

Table of Molecular Bioactivities Related to the Protein

Cell Line ID: CL000901 , 661W

Cell Line Info

Compound ID	Compound Name	Compound Formula
CP0387083 Compound Info	(3aS,9bS)-3a-methyl-5-phenyl-2,3,4,9b-tetrahydro-1H-pyrrolo[2,3-c]quinoline Show/Hide	C18H20N2	1
1	Ki = 1000 nM Bioactivity Info	TI LI LO TS
CP0391120 Compound Info	(1S,2R)-1-ethyl-7-methoxy-2-methyl-3,4-dihydro-1H-naphthalen-2-amine Show/Hide	C14H21NO	1
1	Ki > 10000 nM Bioactivity Info	TI LI LO TS
CP0391121 Compound Info	(3S,4S)-4-ethyl-3,6-dimethyl-2,4-dihydrochromen-3-amine Show/Hide	C13H19NO	1
1	Ki > 10000 nM Bioactivity Info	TI LI LO TS
CP0391154 Compound Info	(3aS,9bS)-7,9-dimethoxy-3a-methyl-2,3,4,9b-tetrahydro-1H-chromeno[3,4-b]pyrrole Show/Hide	C14H19NO3	1
1	Ki > 10000 nM Bioactivity Info	TI LI LO TS
CP0411059 Compound Info	(3S,4S)-4-ethyl-3-methyl-1-phenyl-2,4-dihydroquinolin-3-amine Show/Hide	C18H22N2	1
1	Ki > 10000 nM Bioactivity Info	TI LI LO TS

Cell Line ID: CL000011 , CHO

Cell Line Info

Cell Line ID: CL000026 , CHO-K1

Cell Line Info

Cell Line ID: CL000880 , COS

Cell Line Info

Cell Line ID: CL000109 , COS-1

Cell Line Info

Cell Line ID: CL000053 , COS-7

Cell Line Info

Cell Line ID: CL000006 , HEK293

Cell Line Info

Cell Line ID: CL000065 , HEK293-EBNA

Cell Line Info

Cell Line ID: CL000662 , HL

Cell Line Info

Biochemical Assays

Compound ID	Compound Name	Compound Formula
CP0043740 Compound Info	1-[4-(2-methoxyphenyl)-1-piperazinyl]-3-(1-naphthalenyloxy)-2-propanol;hydrochloride Show/Hide	C24H28N2O3	1
1	IC50 = 55.2 nM
CP0093924 Compound Info	4-hydroxy-7-[(1R)-1-hydroxy-2-[2-[3-[[(2-methoxyphenyl)methylamino]methyl]phenyl]ethylamino]ethyl]-3H-1,3-benzothiazol-2-one Show/Hide	C26H29N3O4S	1
1	IC50 = 199.53 nM
CP0035002 Compound Info	(R)-5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide Show/Hide	C20H28N2O5S	3
1	Ki = 0.058 nM
2	Ki = 0.18 nM
3	Ki = 0.2 nM
CP0040814 Compound Info	[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone Show/Hide	C19H21N5O4	6
1	Ki = 0.2 nM
2	Ki = 0.23 nM
3	Ki = 0.3 nM
4	Ki = 0.3162 nM
5	Ki = 0.32 nM
6	Ki = 0.33 nM
CP0082953 Compound Info	2,3-dihydro-1,4-benzodioxin-3-ylmethyl-[2-(2,6-dimethoxyphenoxy)ethyl]amine;hydrochloride Show/Hide	C19H23NO5	3
1	Ki = 0.2512 nM
2	Ki = 0.5129 nM
3	Ki = 0.8 nM
CP0055045 Compound Info	2-{2-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-ethyl}-4,9-dihydro-2,4,9-triaza-fluorene-1,3-dione Show/Hide	C23H25N5O3	1
1	Ki = 0.3631 nM
CP0061623 Compound Info	8-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)-8-azaspiro[4.5]decane-7,9-dione Show/Hide	C22H31N3O3	4
1	Ki = 0.778 nM
2	Ki = 1.445 nM
3	Ki = 1.6 nM
4	Ki = 6.3 nM
CP0049024 Compound Info	1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine Show/Hide	C19H25N5O4	6
1	Ki = 0.85 nM
2	Ki = 2 nM
3	Ki = 3.467 nM
4	Ki = 3.5 nM
5	Ki = 3.7 nM
6	Ki = 3.981 nM
CP0714031 Compound Info	SID50105948 Show/Hide	C22H33Cl2N3O3	2
1	Ki = 1.047 nM
2	Ki = 6.31 nM
CP0048996 Compound Info	CAS_74191-85-8 Show/Hide	C23H25N5O5	2
1	Ki = 1.2 nM
2	Ki = 3.981 nM
CP0069692 Compound Info	(+)-yohimbine Show/Hide	C21H26N2O3	1
1	Ki = 1.6 nM
CP0048998 Compound Info	5-Chloro-8-methyl-1-vinyl-6,7,8,9-tetrahydro-2-thia-8-aza-benzo[cd]azulene Show/Hide	C14H14ClNS	2
1	Ki = 1.6 nM
2	Ki = 3.162 nM
CP0013593 Compound Info	1-(3-Hydroxy-propyl)-5-((R)-2-{2-[2-(2,2,2-trifluoro-ethoxy)-phenoxy]-ethylamino}-propyl)-2,3-dihydro-1H-indole-7-carboxylic acid amide Show/Hide	C25H32F3N3O4	1
1	Ki = 1.995 nM
CP0345915 Compound Info	3-Methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylic acid {3-[4-(2-methoxy-phenyl)-piperazin-1-yl]-propyl}-amide Show/Hide	C31H33N3O4	1
1	Ki = 2.512 nM
CP0189141 Compound Info	17alpha-hydroxy-20alpha-yohimban-16beta-carboxylic acid methyl ester Show/Hide	C21H26N2O3	1
1	Ki = 3.5 nM
CP0327530 Compound Info	[(4aR,8aS)-4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-2,3,4a,5,6,7,8,8a-octahydroquinoxalin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone Show/Hide	C27H31N5O5	1
1	Ki = 3.89 nM
CP0097484 Compound Info	CYCLAZOSIN Show/Hide	C23H27N5O4	1
1	Ki = 31.62 nM
CP0087323 Compound Info	Niguldipine Show/Hide	C36H39N3O6	1
1	Ki = 100 nM
CP0192450 Compound Info	3-(3-{3-[4-Fluoro-2-(2,2,2-trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propyl)-5-methyl-1H-pyrimidine-2,4-dione Show/Hide	C20H24F4N4O3	1
1	Ki = 100 nM
CP0645895 Compound Info	SID50112869 Show/Hide	C36H40N4O5	3
1	Ki = 537.03 nM
2	Ki = 540 nM
3	Ki = 630 nM
CP0040436 Compound Info	5-N-[3-(4,4-diphenylpiperidin-1-yl)propyl]-3-N,2,6-trimethyl-4-(4-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxamide Show/Hide	C36H41N5O4	2
1	Ki = 616.6 nM
2	Ki = 758.58 nM
CP0037227 Compound Info	7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol Show/Hide	C16H25NO	2
1	Ki < 1000 nM
2	Ki > 1000 nM
CP0002071 Compound Info	N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-prop-2-enylprop-2-en-1-amine Show/Hide	C17H22N2O	1
1	Ki < 10000 nM

Clinical Information about the Protein

Target 1 ( Adrenergic receptor alpha-1D (ADRA1D) )

Target Type	Successful Target
Disease	9 Target-related Diseases				9
1	Benign prostatic hyperplasia [ICD-11: GA90]
2	Pediatric cancer [ICD-11: 2A00-2F9Z]
3	Glaucoma/ocular hypertension [ICD-11: 9C61]
4	Hypertension [ICD-11: BA00-BA04]
5	Erectile dysfunction [ICD-11: HA01.1]
6	Pain [ICD-11: MG30-MG3Z]
7	Urinary incontinence [ICD-11: MF50.2]
8	Prostate disease [ICD-11: GA91]
9	Peripheral vascular disease [ICD-11: BD4Z]
Approved Drug(s)	6 Approved Drugs				6
1	Alfuzosin	Drug Info	Approved	Benign prostatic hyperplasia
2	Armodafinil	Drug Info	Approved	Pediatric cancer
3	Bunazosin	Drug Info	Approved	Glaucoma/ocular hypertension
4	Doxazosin	Drug Info	Approved	Hypertension
5	Moxisylyte	Drug Info	Approved	Erectile dysfunction
6	Terazosin	Drug Info	Approved	Benign prostatic hyperplasia
Clinical Trial Drug(s)	2 Clinical Trial Drugs				2
1	MEDETOMIDINE	Drug Info	Phase 2	Pain
2	DL-017	Drug Info	Phase 1	Hypertension
Discontinued Drug(s)	6 Discontinued Drugs				6
1	INDORAMIN	Drug Info	Withdrawn from market	Hypertension
2	Dabuzalgron	Drug Info	Discontinued in Phase 2	Urinary incontinence
3	FIDUXOSIN HYDROCHLORIDE	Drug Info	Discontinued in Phase 2	Prostate disease
4	NS-49	Drug Info	Discontinued in Phase 2	Urinary incontinence
5	OPC-28326	Drug Info	Discontinued in Phase 2	Peripheral vascular disease
6	REC-15-2739	Drug Info	Discontinued in Phase 2	Prostate disease

Similar Protein(s) and Bioactivity Statistics

50% Identity

Protein ID	Protein Name	Protein Organism
PT02075	Alpha-1D adrenergic receptor	Rattus norvegicus, Rat	Protein Info

Cite

About MolBiC

Correspondence

Prof. Feng ZHU

Prof. Leo, Lianyi Han